Evogene
EVGN
31 hedge funds and large institutions have $754K invested in Evogene in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
19% more funds holding
Funds holding: 26 → 31 (+5)
0.09% less ownership
Funds ownership: 0.35% → 0.27% (-0.09%)
37% less capital invested
Capital invested by funds: $1.2M → $754K (-$442K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
50% less call options, than puts
Call options by funds: $7K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JIC
Joel Isaacson & Co
New York
|
+$21.2K |
| 2 |
Rockefeller Capital Management
New York
|
+$14.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.1K |
| 4 |
LW
Linscomb Wealth
Houston,
Texas
|
+$7.05K |
| 5 |
Morgan Stanley
New York
|
+$4.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
-$191K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$19.2K |
| 3 |
VF
Virtu Financial
New York
|
-$13K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$12.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.58K |
EVGN Hedge Fund Activity: Q4 2022 in Review
31 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2022, worth a combined $754K — down 37% from $1.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EVGN positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Joel Isaacson & Co, opening a new position worth an estimated $21.2K. The largest seller was Senvest Management, exiting entirely with an estimated $191K sold.
- 31 institutional investors held Evogene (EVGN) as of Q4 2022, up from 26 in Q3 2022.
- Funds reported $754K of Evogene stock for Q4 2022, down 37% quarter-over-quarter.
- 9 funds opened new Evogene positions in Q4 2022 and 3 closed out, a net change of +6 holders.
- The largest Evogene buyer in Q4 2022 was Joel Isaacson & Co, an estimated $21.2K added.
- The largest Evogene seller in Q4 2022 was Senvest Management, an estimated $191K sold.
Based on aggregated 13F filings for Q4 2022.